Síntesi i caracterització de micro- i nanoestructures de compostos fotoactius de perilendiimida

En el present treball de recerca s’ha portat a terme la síntesi i caracterització de fibres a escala micro- i nanomètrica mitjançant l’auto-assemblatge dels compostos 1 i 2. Aquests compostos estan formats per una unitat de perilendiimida (PI) i una unitat d’estilbè i, en base a estudis previs desenvolupats al nostre grup de recerca, haurien de comportar-se com a sistemes acceptor-donador d’electrons fotoinduïts. Per tant, les corresponents estructures obtingudes podrien presentar activitat fotovoltaica. En primer lloc, s’ha abordat la síntesi dels compostos 1 i 2, seguint la metodologia posada a punt prèviament al nostre grup de recerca. A continuació, s’han estudiat les propietats òptiques de 1 i 2 en dissolució, la qual cosa ha permès establir que: (a) tal i com es pretenia, tots dos compostos presenten transferència electrònica fotoinduïda entre la unitat electró-acceptora de PI i la unitat electró-donadora de trans-estilbè; (b) la diferent morfologia de la cadena alquílica lateral del grup de PI a 1 i 2 afecta la seva capacitat d’auto-assemblatge mitjançant interaccions intermoleculars de tipus π-π. A continuació, s’han assajat diferents metodologies per a la fabricació de micro- i nanoestructures auto-assemblades de 1 i 2. Els millors resultats s’han obtingut mitjançant l’ús de motlles d’òxid d’alúmina i per al compost 2 degut al menor impediment estèric de la seva cadena alquílica lateral. La caracterització de les estructures resultants en aquest cas mitjançant tècniques microscòpiques i espectroscòpiques han permès demostrar la formació de nanotubs de 200 nm de diàmetre, d’uns 15 μm de longitud i en què les unitats de PI s’ordenen amb els seus sistemes aromàtics de forma co-facial o gairebé co-facial. La possible activitat fotovoltaica d’aquestes estructures s’estudiarà posteriorment.

Desenvolupament d'algorismes biològicament inspirats basats en Support Vector Machines

L'objectiu d'aquest projecte ha estat el desenvolupament d'algorismes biològicament inspirats per a l'olfacció artificial. Per a assolir-lo ens hem basat en el paradigma de les màquines amb suport vectorial. Hem construit algoritmes que imitaven els processos computacionals dels diferents sistemes que formen el sistema olfactiu dels insectes, especialment de la llagosta Schistocerca gregaria. Ens hem centrat en el lòbuls de les antenes, i en el cos fungiforme. El primer està considerat un dispositiu de codificació de les olors, que a partir de la resposta temporal dels receptors olfactius a les antenes genera un patró d'activació espaial i temporal. Quant al cos fungiforme es considera que la seva funció és la d'una memòria per als olors, així com un centre per a la integració multi-sensorial. El primer pas ha estat la construcció de models detallats dels dos sistemes. A continuació, hem utilitzat aquests models per a processar diferents tipus de senyals amb l'objectiu de abstraure els principis computacionals subjacents. Finalment, hem avaluat les capacitats d'aquests models abstractes, i els hem utilitzat per al processat de dades provinents de sensors de gasos. Els resultats mostren que el models abstractes tenen millor comportament front el soroll i més capacitat d'emmagatzematge de records que altres models més clàssics, com ara les memòries associatives de Hopfield o fins i tot en determinades circumstàncies que les mateixes Support Vector Machines.

Boost converter

In this project, we want to implement a theoretical typology of a converter, the Boost converter, which is also named “Step-up converter”. We also want to bring it to the practical area, where we could work and obtain a useful service, particularly our objective is to obtain a power supply for a notebook. We will give the possibility to work, charge etc. our device in the car and obtain another work station

Nevirapine vs efavirenz in virologically supressed patients: Differences in lipoprotein subclasses and inflammatory biomarkers.

Background: The interaction between lipid disturbances and inflammatory markers is not well known in patients on antiretroviral therapy (ART). As nevirapine (NVP) is associated with a better lipid profile than efavirenz (EFV), we investigated the relationships between lipid profiles, lipoprotein subclasses and inflammatory biomarkers in patients with prolonged viral suppression with either NVP or EFV and no obvious clinical inflammation. Methods: 122 clinically stable HIV-infected patients with HIV-1 RNA <20 copies longer than 6 months on NNRTI therapy were studied. 72 (59%) were on EFV and 50 (41%) on NVP. Any potentially inflammatory co-morbid diseases (concurrent viral hepatitis, diabetes, hypertension, chronic liver or renal diseases), or statin treatment, were exclusion criteria. Inflammatory biomarkers included hsCRP, LpPLA2, sCD40L, IL-6, IL-8, t-PA, MCP-1, p-selectin and VCAM-1. Lipoprotein subclass measures (VLDL, LDL, IDL and HDL particle number and size) were obtained by the use of proton nuclear magnetic resonance spectroscopy. Results: 82% were male; median age 45 years. Median CD4 count 550/μL (IQR 324). Median time since HIV diagnosis 96 months (IQR 102) and accumulated time on ART 50 months (IQR 101). Patients on NVP had higher time since HIV diagnosis (126.9 [66.7] vs 91.3 [6.6] months, p=0.008) a prolonged time on ART (89.6 [54.6] vs 62.3 [52.2] months, p=0.01) and were older (47.7 vs 40.7 years, p=0.001) than those on EFV. NVP-treated patients presented increased HDL-c (55.8 [16] vs 48.8 [10.7] mg/dL, p=0.007) and apoA1 levels (153.4 [31.9] vs 141.5 [20.5] mg/dL, p=0.02), and reduced apoB/apoA1 ratio (0.68 [0.1] vs 0.61 [0.1], p=0.003) than EFV-treated patients. No differences in inflammatory markers or lipoprotein subclasses were found between NVP and EFV. In patients with extreme lipid values (less favorable: 75th percentiles of LDL, small/dense LDLp and small HDLp, or more favorable: HDL p75 and apoB/apoA1 ratio p25), no consistent differences in inflammatory biomarkers were found. Conclusions: Patients with prolonged viral suppression on NVP present significantly higher HDL and apoA1 levels and reduced apoB/apoA1 ratios than those on EFV, but no differences were found in lipoprotein particles nor inflammatory biomarkers. Relationships between lipid parameters and inflammatory biomarkers in NNRTItreated patients are complex and do not show a linear relationship in this study.

Plataforma de recollida de signatures digitals per a iniciatives legislatives populars

En aquest TFC s'ha dissenyat i implementat una plataforma de recollida de signatures digitals per a iniciatives legislatives populars (ILPs). Aquesta plataforma dóna la possibilitat a les comissions promotores de crear i gestionar les seves pròpies ILPs i permet als ciutadans signar digitalment aquestes iniciatives de forma que les signatures tinguin validesa legal.

ERP vs software de gestió a entorns complexos de producció

L'objectiu principal de l'estudi és fer una avaluació d'una possible introducció a l'ERP d'un entorn complex de producció com pot ser el món de l'electrònica. Partirem de la hipòtesi que l'empresa vol substituir el software de gestió que fa servir actualment, i que ha estat desenvolupat internament, per plantejar la possibilitat d'introduir aquest entorn sota l'ERP actual o utilitzar un software de gestió de tercers.

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population.

Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to adverse events and group B) subjects switched after a virologic failure on an efavirenz- or nevirapine-based regimen. The primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to suppress plasma HIV-RNA to <50 copies/mL after 24 weeks on treatment, or a confirmed viral load >200 copies/mL in patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9-92.1%) and 77.4% (CI95, 65.0-89.7%), respectively; the rates reached 97.2% (CI95, 95.1-99.3%) and 90.5% (CI95, 81.7-99.3), by on-treatment analysis. The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1-2 adverse events were observed motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable, well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug activity. TRIAL REGISTRATION ClinicalTrials.gov NCT01437241.

Estudios dirigidos a la síntesis de nuevos interruptores moleculares fluorescentes basados en perilendiimidas

Los interruptores moleculares son sistemas moleculares cuyas propiedades pueden ser reversiblemente alternadas entre dos estados diferentes, “On” y “Off”, como respuesta a la aplicación de un estímulo externo. El interruptor molecular fluorescente objetivo de éste trabajo responderá a estímulos fotoquímicos y se detectará por medidas de fluorescencia. En concreto, se ha llevado a cabo la síntesis y caracterización de las tres unidades funcionales que constituyen el interruptor molecular objetivo: dos fluoróforos de perilendiimida y un cromóforo azobencénico.

PARP inhibition attenuates histopathological lesion in ischemia/reperfusion renal mouse model after cold prolonged ischemia.

We test the hypothesis that PARP inhibition can decrease acute tubular necrosis (ATN) and other renal lesions related to prolonged cold ischemia/reperfusion (IR) in kidneys preserved at 4°C in University of Wisconsin (UW) solution. Material and Methods. We used 30 male Parp1(+/+) wild-type and 15 male Parp1(0/0) knockout C57BL/6 mice. Fifteen of these wild-type mice were pretreated with 3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) at a concentration of 15 mg/kg body weight, used as PARP inhibitor. Subgroups of mice were established (A: IR 45 min/6 h; B: IR + 48 h in UW solution; and C: IR + 48 h in UW solution plus DPQ). We processed samples for morphological, immunohistochemical, ultrastructural, and western-blotting studies. Results. Prolonged cold ischemia time in UW solution increased PARP-1 expression and kidney injury. Preconditioning with PARP inhibitor DPQ plus DPQ supplementation in UW solution decreased PARP-1 nuclear expression in renal tubules and renal damage. Parp1(0/0) knockout mice were more resistant to IR-induced renal lesion. In conclusion, PARP inhibition attenuates ATN and other IR-related renal lesions in mouse kidneys under prolonged cold storage in UW solution. If confirmed, these data suggest that pharmacological manipulation of PARP activity may have salutary effects in cold-stored organs at transplantation.

PARP inhibition attenuates histopathological lesion in ischemia/reperfusion renal mouse model after cold prolonged ischemia.

We test the hypothesis that PARP inhibition can decrease acute tubular necrosis (ATN) and other renal lesions related to prolonged cold ischemia/reperfusion (IR) in kidneys preserved at 4°C in University of Wisconsin (UW) solution. Material and Methods. We used 30 male Parp1(+/+) wild-type and 15 male Parp1(0/0) knockout C57BL/6 mice. Fifteen of these wild-type mice were pretreated with 3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) at a concentration of 15 mg/kg body weight, used as PARP inhibitor. Subgroups of mice were established (A: IR 45 min/6 h; B: IR + 48 h in UW solution; and C: IR + 48 h in UW solution plus DPQ). We processed samples for morphological, immunohistochemical, ultrastructural, and western-blotting studies. Results. Prolonged cold ischemia time in UW solution increased PARP-1 expression and kidney injury. Preconditioning with PARP inhibitor DPQ plus DPQ supplementation in UW solution decreased PARP-1 nuclear expression in renal tubules and renal damage. Parp1(0/0) knockout mice were more resistant to IR-induced renal lesion. In conclusion, PARP inhibition attenuates ATN and other IR-related renal lesions in mouse kidneys under prolonged cold storage in UW solution. If confirmed, these data suggest that pharmacological manipulation of PARP activity may have salutary effects in cold-stored organs at transplantation.